Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial.

Axel Stenmark Tullberg Henri A J Puttonen Martin Sjostrom Erik Carl Viktor HolmbergS Laura ChangFelix Y FengCorey W SpeersLori J PierceDan LundstedtFredrika KillanderEmma NiméusAnikó Kovacs Per Karsson

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Patients with an antitumoral immune infiltrate in the primary tumor have a reduced risk of any recurrence and may derive less benefit from adjuvant radiotherapy. These results may impact decisions regarding postoperative radiotherapy in early breast cancer.

Keyphrases

early stage
locally advanced
early breast cancer
phase iii
radiation therapy
radiation induced
phase ii
open label
clinical trial
double blind
patients undergoing
squamous cell carcinoma
randomized controlled trial